Primary Radiotherapy In MEtastatic Lung Cancer

Primary Radiotherapy In MEtastatic Lung Cancer is a phase 3, randomised interventional study registered as NCT07135882 by Trans Tasman Radiation Oncology Group, with a registry enrolment figure of 420 participants, started 2026-08-25 and due to reach its primary completion in 2030-12-31. Interventions recorded: Radiotherapy followed by chemotherapy; Standard of Care (SOC). Conditions listed: Carcinoma, Non-Small-Cell Lung (NSCLC). Primary outcome: Overall survival. Lung eligibility wording from the registry: "* Newly diagnosed metastatic (stage IV) NSCLC, not amenable to curative surgery or curative radiotherapy". Sites: Australia. No results are recorded here; the registry entry is the source.